Funding agency DST

Start date March 27, 2023

End Date None

Duration None

Disease category Spinal Muscular Atrophy

Type of study Invitro study

Type of data Quantitative data

Aims of objective • An indigenous synthetic process route/technology for the development of generic Nusinersen. • Innovative Elements of the Project: Improved synthesis of 2’-O-MOE phosphoramidite monomers through appropriate modification ofreported procedures. • Shortened solid phase synthesis cycle by avoiding a separate capping step; achieving sulfurizationand capping in the same step through re-circulation of reagents.

Keyword Nusinersen, Orphan drug, Spinal Muscular Atrophy

Description None

Total Sanctioned budget None